NewsMV
In focus for SPRY holders: Pomerantz LLP disclosed on July 9, 2026, that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc.
The New York firm named Danielle Peyton as the attorney handling investor outreach. No formal complaint has been announced.
The investigation The July 9 alert from Pomerantz LLP did not identify the specific claims under review, the conduct at issue, or a defined class period.
The firm published no financial figures, no alleged damage estimates, and no regulatory findings.
Keep reading